PUBLIC COMPANY
save$IDYAIDEAYA Biosciences, Inc.
$IDYA38.09-0.86%South San Francisco, CA, USupdated 3h ago
community read0 votes
pipeline
9
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(9)
pipeline depth9 products
1Preclinical3Phase 14Phase 21Phase 3
Phase 3
darovasertib
Metastatic Uveal Melanoma
Phase 2IDE-161
Colon Cancer
Phase 2IDE-275
Endometrial Cancer
Phase 2IDE-397
Adenoid Cystic Carcinoma (ACC)
Phase 2SHR-4849
Neuroendocrine Tumors
Phase 1IDE-034
Castration-Resistant Prostate Cancer (CRPC)
Phase 1IDE-574
Breast Cancer
Phase 1IDE-892
Esophageal Squamous Cell Carcinoma (ESCC)
PreclinicalCDKN2A Program
Pancreatic Cancer
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
- phase2A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
- phase1Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- phase1A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- phase1A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- phase2(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
- phase3Neoadjuvant Darovasertib in Primary Uveal Melanoma
- phase3IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
🐶 Hiring Signal
News
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.biopharma_dive · 3d ago
- Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugPlus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will…endpoints · 3mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that